Table 1.

Pharmaceutical intervention with anti-CD47, anti-SIRPα, and thrombocytopenia in clinical trials.

Strategy to minimize anemia	Reagent (company)	Thrombocytopenia in clinical trials:
Priming dose to ramp up red blood cell production	Magrolimab (Gilead)	55% (https://ascopubs.org/doi/full/10.1200/JCO.22.01794)
Intratumoral injection	TTI-621 (Trillium)	Observed transient decline in platelet levels (when injected IV) Thrombocytopenia (grade 3 or above) as treatment related adverse event in 20% of patients. (https://aacrjournals.org/clincancerres/article/27/8/2190/672069/Phase-I-Study-of-the-CD47-Blocker-TTI-621-in)
Glycosylation specific antibody binding	Lemzoparlimab/TJC4 (I-mab)	In combination with Azacitidine (AZA) treatment, there was decreased platelet count (60%). EMSO Sept. 10, 2022 PDF
Antibody binding only CD47 in complex with integrin B1	AO-176 (Arch Oncology)	Thrombocytopenia as treatment related adverse event in 9/27 (33%) patients (https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.2516).
Inert FC	ALX148 (ALX Oncology)	Thrombocytopenia as treatment related adverse event in 10% of patients. (https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.3056)
Antibody SIRPα binding to prevent Fcγ receptor recognition	GS-0189 (Gilead)	Thrombocytopenia not observed as a treatment related adverse event in patients. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188468/)
High affinity binding to V1 SIRPα allele	BI 765063 (Boehringer Ingelheim)	No related anemia of thrombocytopenia observed. (https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.2623)